(Q33998367)

30 July 2017

1 reference

title

Third-generation thrombolytic drugs (English)

1 reference

30 July 2017

1 reference

Verstraete M

1

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 July 2000

1 reference

American Journal of Medicine

30 July 2017

published in

1 reference

30 July 2017

volume

109

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

52-58

1 reference

Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

TIMI frame count: a quantitative method of assessing coronary artery flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thromb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Change in ST segment elevation 60 minutes after thrombolytic initiation predicts clinical outcome as accurately as later electrocardiographic changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

A faster-acting and more potent form of tissue plasminogen activator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Kranken

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

A comparison of reteplase with alteplase for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Staphylokinase; an activator of plasma protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

A proteolytic enzyme system of the blood. III. Activation of dog serum profibrinolysin by staphylokinase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Interaction of staphylokinase with different molecular forms of plasminogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2800%2900380-6

10.1016/S0002-9343(00)00380-6

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference